ArticleJournal of clinical microbiology2009
Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Azole Antifungal Consumption in Community Pharmacy Sales in Mainland Portugal: Trend Analysis from 2014 to 2023.Antibiotics (Basel, Switzerland) · 2025Article
- Phenotypic and genomic characterization of azole resistance in PortugueseFrontiers in fungal biology · 2025Article
- Article
- A genome-informed higher rank classification of the biotechnologically important fungal subphylumStudies in mycology · 2023Article
- Global Prevalence of Antifungal-ResistantTropical medicine and infectious disease · 2022Review
- Identification of a novel Candida metapsilosis isolate reveals multiple hybridization events.G3 (Bethesda, Md.) · 2022Article
- The transcription factor Ndt80 is a repressor of Candida parapsilosis virulence attributes.Virulence · 2021Article
- Species Distribution, Antifungal Susceptibility, and Molecular Epidemiology ofJournal of fungi (Basel, Switzerland) · 2021Article
- Article
- Antimicrobial activity ofJournal of food science and technology · 2020Article
- Capability of Fluorescent Capillary Electrophoresis To Distinguish Species of theJournal of clinical microbiology · 2019Article
- Yeast Biofilm as a Bridge Between Medical and Environmental Microbiology Across Different Detection Techniques.Infectious diseases and therapy · 2018Article
- Identification and antifungal susceptibility of Candida species isolated from the urine of patients in a university hospital in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2017Article
- Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens.Journal of biomedical science · 2017Article
- Regulation of ERG3, ERG6, and ERG11 Genes in Antifungal-Resistant isolates of Candida parapsilosisIranian biomedical journal · 2017Article
- Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing.Antimicrobial agents and chemotherapy · 2017Article
- Comparison of four molecular approaches to identify Candida parapsilosis complex species.Memorias do Instituto Oswaldo Cruz · 2017Article
- Caspofungin-Non-SusceptibleIranian journal of public health · 2017Article
- Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit.BMC infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida parapsilosis, an emergent agent of nosocomial infections, was previously made up of a complex of three genetically distinct groups (groups I, II, and III). Recently, the C. parapsilosis groups have been renamed as distinct species: C. parapsilosis sensu stricto, C. orthopsilosis, and C. metapsilosis. In Portugal, no data pertaining to the distribution and antifungal susceptibility of these Candida species are yet available. In the present report, we describe the incidence and distribution of C. parapsilosis sensu stricto, C. orthopsilosis, and C. metapsilosis among 175 clinical and environmental isolates previously identified by conventional methods as C. parapsilosis. We also evaluated the in vitro susceptibilities of the isolates to fluconazole, voriconazole, posaconazole, amphotericin B, and two echinocandins, caspofungin and anidulafungin. Of the 175 isolates tested, 160 (91.4%) were identified as C. parapsilosis sensu stricto, 4 (2.3%) were identified as C. orthopsilosis, and 5 (2.9%) were identified as C. metapsilosis. Six isolates corresponded to species other than the C. parapsilosis group. Interestingly, all isolates from blood cultures corresponded to C. parapsilosis sensu stricto. Evaluation of the antifungal susceptibility profile showed that only nine (5.6%) C. parapsilosis sensu stricto strains were susceptible-dose dependent or resistant to fluconazole, and a single strain displayed a multiazole-resistant phenotype; two (1.3%) C. parapsilosis sensu stricto strains were amphotericin B resistant. All C. orthopsilosis and C. metapsilosis isolates were susceptible to azoles and amphotericin B. A high number of strains were nonsusceptible to the echinocandins (caspofungin and anidulafungin).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.